Exicure (XCUR) Restructuring Costs (2023 - 2024)
Exicure's (XCUR) quarterly Restructuring Costs came in at $424000.0 in Q4 2024, down 54.8% YoY from $938000.0 in Q1 2024, and down 62.74% on a QoQ basis from $1.1 million in Q3 2024.
Exicure (XCUR) Restructuring Costs (2023 - 2024) Analysis & Trends
Exicure (XCUR) has 2 years of Restructuring Costs data on file, last reported at $424000.0 in Q4 2024.
- Quarterly Restructuring Costs fell 54.8% year-over-year to $424000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2025 was $1.6 million (down 37.52% YoY) and the FY2024 annual result came in at $1.6 million, up 66.52% from the prior year.
- Restructuring Costs fell to $424000.0 in Q4 2024, from $1.1 million in the prior quarter.
- In the past five years, Restructuring Costs ranged from a high of $1.1 million in Q3 2024 to a low of $424000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Exicure | 8.41 Mn | 8.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 424,000.00 |
| Sep 30, 2024 | 1.14 Mn |
| Dec 31, 2023 | 938,000.00 |